Manufacturing And Supply ChainA multi-year manufacturing agreement with CordenPharma has been made to ensure supply for VK2735, which is seen as a positive step in derisking the supply chain for commercialization.
Patient Access And Market ExpansionThe availability of intermediary doses in the Phase III program could increase patient access, especially for smaller-scale or community-based clinics.
Program InitiationThe initiation of the Phase 3 Obesity VANQUISH studies with VK2735 reflects Viking Therapeutics' progress and the potential value in their obesity and metabolic disease programs.